Acuta Capital Partners, LLC Ascendis Pharma A/S Transaction History
Acuta Capital Partners, LLC
- $70.3 Million
- Q4 2024
A detailed history of Acuta Capital Partners, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 22,976 shares of ASND stock, worth $3.27 Million. This represents 4.5% of its overall portfolio holdings.
Number of Shares
22,976
Previous 21,000
9.41%
Holding current value
$3.27 Million
Previous $3.14 Million
0.86%
% of portfolio
4.5%
Previous 3.18%
Shares
12 transactions
Others Institutions Holding ASND
# of Institutions
234Shares Held
58.9MCall Options Held
208KPut Options Held
321K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.38 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$788 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$727 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$634 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$597 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.95B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...